Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Operating Leases (2023 - 2025)

Telix Pharmaceuticals has reported Operating Leases over the past 3 years, most recently at $62.1 million for Q4 2025.

  • Quarterly Operating Leases rose 1066.11% to $62.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $62.1 million through Dec 2025, up 1066.11% year-over-year, with the annual reading at $62.1 million for FY2025, 842.35% up from the prior year.
  • Operating Leases was $62.1 million for Q4 2025 at Telix Pharmaceuticals, up from $5.3 million in the prior quarter.
  • Over five years, Operating Leases peaked at $62.1 million in Q4 2025 and troughed at $5.0 million in Q4 2023.
  • The 3-year median for Operating Leases is $5.3 million (2024), against an average of $24.1 million.
  • Year-over-year, Operating Leases rose 6.53% in 2024 and then soared 1066.11% in 2025.
  • A 3-year view of Operating Leases shows it stood at $5.0 million in 2023, then rose by 6.53% to $5.3 million in 2024, then soared by 1066.11% to $62.1 million in 2025.
  • Per Business Quant, the three most recent readings for TLX's Operating Leases are $62.1 million (Q4 2025), $5.3 million (Q4 2024), and $5.0 million (Q4 2023).